Announcements Trials

Browse Landscape

Phase

Phase 3 2 Phase 2 1 Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 242 Carboplatin 135 Nivolumab 132 Gemcitabine 127 Paclitaxel 116 Cisplatin 105 Bevacizumab 95 Cyclophosphamide 93 Dexamethasone 78 Injections 75 Docetaxel 72 Pemetrexed 71 Fluorouracil 68 Capecitabine 65 Rituximab 61 Cetuximab 61 atezolizumab 60 130-nm albumin-bound paclitaxel 59 Oxaliplatin 58 Leucovorin 56 Ipilimumab 54 fludarabine 47 Lenalidomide 47 Azacitidine 40 Irinotecan 39 venetoclax 38 Fulvestrant 38 Albumin-Bound Paclitaxel 36 Prednisone 35 Trastuzumab 34

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × INDUSTRY × zipalertinib × Clear all

NCT04036682 2025-03-13

REZILIENT1

Cullinan Therapeutics Inc.

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡